China's Luye Pharma expands collaboration with Elpis

7 June 2018

China's Luye Pharma (SEHK: 2186) has partnered up with US biotech firm Elpis Biopharmaceuticals to work on dual target based therapies for cancer patients who fail to respond to current treatment.

As a continuing effort of the collaboration initiated last year, the two companies signed a license agreement recently to jointly develop chimeric antigen receptor T-cell (CAR-T) therapies and biologic drug candidates in immuno-oncology.

"This is a global collaboration. Luye will be in charge of the development and commercialization of the co-developed products in China and will have the exclusive rights in the Chinese market," noted Sammy Jiang, vice president of strategy and business development at Luye.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK